GT Biopharma Explores A New Combination Approach For Pancreatic Cancer

Key Points

• GT Biopharma is exploring ways to use its TriKE® immunotherapy platform against solid tumors, including pancreatic cancer, where treatment resistance remains a major challenge.

• New preclinical research found that combining GTB-5550 with a KRAS inhibitor improved tumour control, increased immune cell activity and prevented cancer from spreading in laboratory models.

• The findings could give GT Biopharma another potential development opportunity, although the combination has not yet been tested in human patients.

• Investors will be watching whether the encouraging laboratory results translate into clinical progress and whether the company can demonstrate that GTB-5550 works effectively alongside existing cancer treatments.

GT Biopharma explores a different approach to pancreatic cancer

GT Biopharma (NASDAQ:GTBP) has presented new research exploring whether its experimental cancer treatment, GTB-5550, could work more effectively when combined with an existing type of targeted cancer therapy.

Presented at the Society for Immunotherapy of Cancer (SITC) 2026 Annual Meeting, the research focused on pancreatic cancer and the potential benefits of combining GTB-5550 with a KRAS inhibitor.

The findings suggest that using the two treatments together could help the body's immune system attack cancer cells more effectively.

This is potentially important for GT Biopharma because developing treatments for solid tumours, including pancreatic cancer, has been a difficult area for immunotherapy companies.

While the research is still at an early stage, it offers another indication of how the company's technology could potentially be used beyond its current clinical program.

Why combining two cancer treatments could make a difference

GTB-5550 is designed to help natural killer (NK) cells recognise and destroy cancer cells.

These cells are part of the body's immune system and play an important role in fighting disease. GTB-5550 uses the company's TriKE® technology to direct NK cells towards cancer cells and strengthen their ability to attack them.

The latest research looked at whether combining this approach with a KRAS inhibitor could improve the results.

KRAS is a gene that can contribute to cancer growth when it becomes mutated. Treatments that target KRAS can slow or stop this growth, but cancer cells can sometimes find ways around these treatments and continue developing.

GT Biopharma's combination approach aims to tackle the problem from two directions: slowing cancer growth with a targeted treatment while also encouraging the immune system to attack the tumour.

In laboratory models of pancreatic cancer, the combination produced several encouraging results:

• Better tumour control than treatment with the KRAS inhibitor alone.

• Complete tumour clearance in several animals.

• Reduced tumour invasion and no observed spread to other parts of the body.

• Twice as many NK cells entering the tumours.

• Increased activity and persistence of the transferred NK cells.

• Higher levels of cancer cell death.

Put simply, the research suggests that blocking KRAS could make pancreatic cancer cells more vulnerable to attack by the immune system.

However, it is important to remember that these results came from preclinical models. They do not yet tell us whether the same benefits will occur in people.

GTB-5550 moves closer to an important clinical test

The announcement comes as GT Biopharma continues enrolling patients in its Phase 1a/1b clinical trial of GTB-5550 (NCT07541573).

The trial is evaluating GTB-5550 as a standalone treatment across several cancer types, including pancreatic ductal adenocarcinoma.

Executive Chairman and CEO Michael Breen said the company continues to make progress with patient enrollment in the ongoing study.

Management also indicated that it is considering a potential Phase 1b study combining GTB-5550 with a KRAS inhibitor.

This could be an important next step for the company.

Rather than developing GTB-5550 only as a standalone treatment, GT Biopharma appears to be exploring whether its technology could also improve the effectiveness of other cancer therapies.

That could broaden the potential applications of the platform and create additional opportunities within the solid tumour market.

However, the company has not yet committed to starting the combination study or provided a timeline.

For investors, the immediate priority remains the ongoing clinical trial. Results from human patients will be much more meaningful in assessing whether GTB-5550 is safe and whether it can produce the intended effects.

Combination treatments are becoming increasingly important in cancer research

GT Biopharma's latest findings reflect a wider shift in cancer treatment development.

Researchers are increasingly exploring combinations of treatments that attack cancer in different ways. Targeted therapies can interfere with the processes that help cancer cells grow, while immunotherapies aim to help the body's own defences recognise and destroy them.

The idea is that combining these approaches could potentially deliver better results than using either treatment alone.

This is particularly relevant in pancreatic cancer, where treatment options remain challenging and tumours can be difficult for the immune system to attack.

If GTB-5550 can demonstrate meaningful benefits alongside KRAS inhibitors in human studies, it could give GT Biopharma another way to develop its technology and potentially expand its reach across different cancer types.

There is still considerable work ahead, though. The company will need to demonstrate safety, clinical benefits and a clear reason for doctors to consider the combination over existing treatment options.

What investors may watch next

The latest research provides encouraging support for GT Biopharma's approach, but the next stage will be about turning laboratory findings into meaningful clinical progress.

Investors may want to keep an eye on:

• Clinical trial progress: Patient enrollment and early safety and efficacy results from the ongoing GTB-5550 Phase 1a/1b study.

• Combination study plans: Whether management formally moves ahead with a study combining GTB-5550 and a KRAS inhibitor.

• Evidence in human patients: Whether the improvements seen in preclinical models can be reproduced in clinical trials.

• Broader applications: Whether GTB-5550 shows potential across other solid tumours, creating additional opportunities for the TriKE® platform.

Ultimately, the latest announcement adds another interesting development to GT Biopharma's pipeline. The combination approach could expand the potential of GTB-5550, particularly in a difficult-to-treat cancer such as pancreatic cancer.

But for investors, the biggest milestone will be seeing whether these early results translate into genuine progress in human clinical trials.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com